This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Thanks! I will follow this study. But not sure - as we are in Switzerland we have limited access to the studies and we just there was just the chance to participate in the current 661 combo study for DD508 and residual function. But as my son being too young no way of getting into. Status is...
If they included specific mutations they would have to mention it, right? I would suppose their inclusion parameters are clearly stated and they include every mutation accordingly. My son has R347P which is was not mentioned to respond in the in vitro studies. In real life, my son (11 years) is...
R347p
Hi - may I ask are you still on Kalydeco and still keeping the good results? We are in the same boat with R347P - Class 4/Conductance, not responsive in vitro but also PS and very keen to try Kalydecco or - as DF508 as well - the combination drug.
Steve, my son has DeltaF508 and R347P (class IV). The only thing I know about class IV mutations is that patients are often pancreatic sufficient (and my son is). Do you have any insight about this specific mutation? Thank you.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.